Experience

Q-VANT Biosciences

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Vice President Of Business Development

  • Jan 2022 - Present

  Q-VANT is a privately held company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company’s next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 – enabling the production of billions of doses annually to meet today’s increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Show less



Stein ApS

• Copenhagen Area, Denmark

• Executive Advisor

  • Mar 2017 - Present

  Strategy development and execution, business development; Vaccines, pharmaceuticals. Main experience: Global Projects. Pharmaceutical starting materials/intermediates, vaccine adjuvants Strategy development and execution, business development; Vaccines, pharmaceuticals. Main experience: Global Projects. Pharmaceutical starting materials/intermediates, vaccine adjuvants



CS MEDICA

• Denmark
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Non Executive Board Member

  • Mar 2021 - Mar 2023



Brenntag Biosector A/S (now: Croda Denmark)

• Frederikssund, Capital Region, Denmark

• General Manager

  • Oct 2007 - Feb 2016

  Responsible for vision, strategy and full P&L for Brenntag Biosector – a commercial vaccine adjuvant company. To execute these responsibilities, I lead a diverse team who managed each of the functional areas in the company. Biosector is a life sciences company which manufactures and sells high quality adjuvants, not just for today’s vaccines, but also for the vaccines of tomorrow as well as for research in experimental immunology. Every year about 2,5 bio. vaccine dosages are produced globally with adjuvants from Brenntag Biosector. Customers are located in 45 countries. The development work is focused on applying the technology to help vaccinologists facilitating rational vaccine design. The products are also used by collectors of human plasma in the fractionation process. Show less



Brenntag

• Germany
• Chemical Manufacturing
• 700 & Above Employee

• Business Unit Director - HealthCare

  • Jan 2004 - Oct 2007

  Led the development of the Nordic Brenntag distribution activities of - starting materials for pharmaceuticals and natural medicines, - ingredients for cosmetics and - sales and manufacturing of disinfectants for hospital use. Established a laboratory for cosmetics applications, and a distribution center working according to GMP. Head of Vaccine Adjuvant activities since 2005. Brenntag became market leader in each of these business areas.

• Facilitator - European Pharmaceutical Business

  • 2002 - 2006

  Development of European strategy for the Brenntag pharma business; advised and monitored the European country organisations in implementing the strategy.Formed a Pan European group of specialists in the business of pharmaceutical starting materials; Shaped the group as a team with common targets and, coordinated the pharma business in Brenntag Europe.Facilitated the development of Good Trade and Distribution Practices at Brenntag sites across EuropeIdentified acquisition targets.Responsible for revenue growth. Show less



European Association of Chemical Distributors

• Belgium
• Chemical Manufacturing
• 1 - 100 Employee

• Chairman of Life Sciences Committee

  • 2002 - 2006

  Together with the committee members, I developed and formulated the position of chemical distributors on issues of common relevance related to food, pharma, cosmetics and feed activities. I took active part in the policy-making process on these issues in Europe through the EU, and globally through WHO. We initiated and implemented industry training and education on how to meet future regulatory challenges. Together with the committee members, I developed and formulated the position of chemical distributors on issues of common relevance related to food, pharma, cosmetics and feed activities. I took active part in the policy-making process on these issues in Europe through the EU, and globally through WHO. We initiated and implemented industry training and education on how to meet future regulatory challenges.



Brenntag Nordic A/S

• Hellerup, Capital Region, Denmark

• Divisional Director

  • 2000 - 2004



Superfos Chemicals A/S - HealthCare Division

• Divisional Director - Nordic

  • 1999 - 2000



Superfos Kemi A/S

• Divisional Manager - Denmark

  • 1997 - 1999



Nordisk Droge Handels A/S

• Divisional Manager

  • 1994 - 1996

• Purchasing and Supply Chain Manager

  • 1991 - 1996